{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:38:18Z","timestamp":1793147898115,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>COVID-19 vaccinations are essential to mitigate the pandemic and prevent severe SARS-CoV-2 infections. However, the serum antibody levels in vaccinated individuals gradually decrease over time, while SARS-CoV-2 is undergoing an evolution toward more transmissible variants, such as B.1.617.2, ultimately increasing the risk of breakthrough infections and further virus spread. This cross-sectional online study of adult Poles (n = 2427) was conducted in September 2021 (before a general recommendation to administer a booster COVID-19 vaccine dose in Poland was issued) to assess the attitude of individuals who completed the current vaccination regime toward a potential booster dose of the COVID-19 vaccine and identify potential factors that may influence it. Overall, 71% of participants declared willingness to receive a booster COVID-19 dose, with a low median level of fear of receiving it of 1.0 (measured by the 10-point Likert-type scale), which was increased particularly in those having a worse experience (in terms of severity of side effects and associated fear) with past COVID-19 vaccination. The lowest frequency of willingness to receive a booster dose (26.7%) was seen in the group previously vaccinated with Ad26.COV2.S. The majority of individuals vaccinated previously with mRNA vaccines wished to receive the same vaccine, while in the case of AZD1222, such accordance was observed only in 9.1%. The main reasons against accepting a booster COVID-19 dose included the side effects experienced after previous doses, the opinion that further vaccination is unnecessary, and safety uncertainties. Women, older individuals (\u226550 years), subjects with obesity, chronic diseases, and pre-vaccination and post-vaccination SARS-CoV-2 infections, and those with a history of vaccination against influenza were significantly more frequently willing to receive a booster COVID-19 dose. Moreover, the majority of immunosuppressed individuals (88%) were willing to receive an additional dose. The results emphasize some hesitancy toward potential further COVID-19 vaccination in the studied group of Poles and indicate the main groups to be targeted with effective science communication regarding the booster doses.<\/jats:p>","DOI":"10.3390\/vaccines9111286","type":"journal-article","created":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T20:42:54Z","timestamp":1636317774000},"page":"1286","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4713-0801","authenticated-orcid":false,"given":"Piotr","family":"Rzymski","sequence":"first","affiliation":[{"name":"Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"},{"name":"Integrated Science Association (ISA), Universal Scientific Education and Research Network (USERN), 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1601-1703","authenticated-orcid":false,"given":"Barbara","family":"Poniedzia\u0142ek","sequence":"additional","affiliation":[{"name":"Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9675-7942","authenticated-orcid":false,"given":"Andrzej","family":"Fal","sequence":"additional","affiliation":[{"name":"Collegium Medicum, Warsaw Faculty of Medicine, Cardinal Stefan Wyszy\u0144ski University, 01-938 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Nowakowska, J., Soboci\u0144ska, J., Lewicki, M., Lema\u0144ska, \u017b., and Rzymski, P. (2020). When science goes viral: The research response during three months of the COVID-19 outbreak. Biomed. Pharmacother., 129.","DOI":"10.1016\/j.biopha.2020.110451"},{"key":"ref_2","unstructured":"Di\u00e9guez-Campa, C.E., P\u00e9rez-Neri, I., Reyes-Ter\u00e1n, G., Flores-Apodaca, I.A., Castillo-Led\u00f3n-Pretelini, J., Mercado-Bautista, O., \u00c1lvarez-Santana, R., Zenteno, M.A., Bowles, B., and Lee, \u00c1. (2020). The 2020 research pandemic: A bibliometric analysis of publications on COVID-19 and their scientific impact during the first months. Arch. Cardiol. Mex."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Pazgan-Simon, M., Simon, K., \u0141api\u0144ski, T., Zar\u0119bska-Michaluk, D., Szczepa\u0144ska, B., Chojnicki, M., Mozer-Lisewska, I., and Flisiak, R. (2021). Clinical Characteristics of Hospitalized COVID-19 Patients Who Received at Least One Dose of COVID-19 Vaccine. Vaccines, 9.","DOI":"10.3390\/vaccines9070781"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(21)01642-1","article-title":"Spike-antibody waning after second dose of BNT162b2 or ChAdOx1","volume":"398","author":"Shrotri","year":"2021","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Yamayoshi, S., Yasuhara, A., Ito, M., Akasaka, O., Nakamura, M., Nakachi, I., Koga, M., Mitamura, K., Yagi, K., and Maeda, K. (2021). Antibody titers against SARS-CoV-2 decline, but do not disappear for several months. EClinicalMedicine, 32.","DOI":"10.1016\/j.eclinm.2021.100734"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mlcochova, P., Kemp, S., Dhar, M.S., Papa, G., Meng, B., Ferreira, I.A.T.M., Datir, R., Collier, D.A., Albecka, A., and Singh, S. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature.","DOI":"10.21203\/rs.3.rs-637724\/v1"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jinf.2021.08.027","article-title":"The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients","volume":"83","author":"Teyssou","year":"2021","journal-title":"J. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Thomas, S.J., Moreira, E.D., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., P\u00e9rez Marc, G., Polack, F.P., and Zerbini, C. (2021). Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. medRxiv.","DOI":"10.1101\/2021.07.28.21261159"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 Vaccines against the B.1.617.2 (Delta) Variant","volume":"385","author":"Andrews","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Tang, P., Hasan, M.R., Chemaitelly, H., Yassine, H.M., Benslimane, F.M., Khatib, H.A.A., AlMukdad, S., Coyle, P., Ayoub, H.H., and Kanaani, Z.A. (2021). BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar. medRxiv.","DOI":"10.1101\/2021.08.11.21261885"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Chia, P.Y., Xiang Ong, S.W., Chiew, C.J., Ang, L.W., Chavatte, J.-M., Mak, T.-M., Cui, L., Kalimuddin, S., Chia, W.N., and Tan, C.W. (2021). Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: A multi-center cohort study. medRxiv.","DOI":"10.1101\/2021.07.28.21261295"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pouwels, K.B., Pritchard, E., Matthews, P.C., Stoesser, N., Eyre, D.W., Vihta, K.-D., House, T., Hay, J., Bell, J.I., and Newton, J.N. (2021). Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. medRxiv.","DOI":"10.1101\/2021.08.18.21262237"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Riemersma, K.K., Grogan, B.E., Kita-Yarbro, A., Halfmann, P.J., Segaloff, H.E., Kocharian, A., Florek, K.R., Westergaard, R., Bateman, A., and Jeppson, G.E. (2021). Shedding of Infectious SARS-CoV-2 Despite Vaccination. medRxiv.","DOI":"10.1101\/2021.07.31.21261387"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Liu, Y., and Rockl\u00f6v, J. (2021). The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J. Travel Med.","DOI":"10.1093\/jtm\/taab124"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Burki, T.K. (2021). Lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir. Med., 9.","DOI":"10.1016\/S2213-2600(21)00328-3"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Stumpf, J., Siepmann, T., Lindner, T., Karger, C., Schw\u00f6bel, J., Anders, L., Faulhaber-Walter, R., Schewe, J., Martin, H., and Schirutschke, H. (2021). Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg. Health-Eur., 9.","DOI":"10.1016\/j.lanepe.2021.100178"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Schmidt, T., Klemis, V., Schub, D., Schneitler, S., Reichert, M.C., Wilkens, H., Sester, U., Sester, M., and Mihm, J. (2021). Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. Am. J. Transplant.","DOI":"10.1111\/ajt.16818"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Thuluvath, P.J., Robarts, P., and Chauhan, M. (2021). Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. J. Hepatol., in press.","DOI":"10.1016\/j.jhep.2021.08.008"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three Doses of an mRNA COVID-19 Vaccine in Solid-Organ Transplant Recipients","volume":"385","author":"Kamar","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jama.2021.11656","article-title":"Age-Dependent Neutralization of SARS-CoV-2 and P.1 Variant by Vaccine Immune Serum Samples","volume":"326","author":"Bates","year":"2021","journal-title":"JAMA"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"M\u00fcller, L., Andr\u00e9e, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., and Rabl, D. (2021). Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination. Clin. Infect. Dis.","DOI":"10.1101\/2021.03.03.21251066"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"ref_29","unstructured":"European Medicine Agency (2021, September 13). ECDC and EMA Highlight Considerations for Additional and Booster Doses of COVID-19 Vaccines. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ecdc-ema-highlight-considerations-additional-booster-doses-COVID-19-vaccines."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(21)02046-8","article-title":"Considerations in boosting COVID-19 vaccine immune responses","volume":"398","author":"Krause","year":"2021","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/s41591-021-01494-4","article-title":"COVID-19 boosters in rich nations will delay vaccines for all","volume":"27","author":"Chagla","year":"2021","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Geldsetzer, P. (2020). Use of Rapid Online Surveys to Assess People\u2019s Perceptions During Infectious Disease Outbreaks: A Cross-sectional Survey on COVID-19. J. Med. Internet Res., 22.","DOI":"10.2196\/preprints.18790"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Zeyland, J., Poniedzia\u0142ek, B., Ma\u0142ecka, I., and Wysocki, J. (2021). The Perception and Attitudes toward COVID-19 Vaccines: A Cross-Sectional Study in Poland. Vaccines, 9.","DOI":"10.3390\/vaccines9040382"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Cascini, F., Pantovic, A., Al-Ajlouni, Y., Failla, G., and Ricciardi, W. (2021). Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: A systematic review. EClinicalMedicine, 40.","DOI":"10.1016\/j.eclinm.2021.101113"},{"key":"ref_35","first-page":"262","article-title":"Acceptance of a COVID-19 Vaccine and Its Related Determinants among the General Adult Population in Kuwait","volume":"30","author":"Alqudeimat","year":"2021","journal-title":"Med. Princ. Pract. Int. J. Kuwait Univ. Health Sci. Cent."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Grochowska, M., Ratajczak, A., Zdunek, G., Adamiec, A., Waszkiewicz, P., and Feleszko, W. (2021). A Comparison of the Level of Acceptance and Hesitancy towards the Influenza Vaccine and the Forthcoming COVID-19 Vaccine in the Medical Community. Vaccines, 9.","DOI":"10.3390\/vaccines9050475"},{"key":"ref_37","unstructured":"Cochran, W.G. (1977). Sampling Techniques, Wiley. [3rd ed.]."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Albano, L., Matuozzo, A., Marinelli, P., and Di Giuseppe, G. (2014). Knowledge, attitudes and behaviour of hospital health-care workers regarding influenza A\/H1N1: A cross sectional survey. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-208"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Costantino, C., Amodio, E., Vitale, F., Trucchi, C., Maida, C.M., Bono, S.E., Caracci, F., Sannasardo, C.E., Scarpitta, F., and Vella, C. (2020). Human Papilloma Virus Infection and Vaccination: Pre-Post Intervention Analysis on Knowledge, Attitudes and Willingness to Vaccinate Among Preadolescents Attending Secondary Schools of Palermo, Sicily. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17155362"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.bjc.6604454","article-title":"Human papillomavirus and vaccination: Knowledge, attitudes, and behavioural intention in adolescents and young women in Italy","volume":"99","author":"Abbate","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Napolitano, F., Napolitano, P., and Angelillo, I.F. (2017). Seasonal influenza vaccination in pregnant women: Knowledge, attitudes, and behaviors in Italy. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-016-2138-2"},{"key":"ref_42","unstructured":"(2021, September 13). CBOS. Research Reports. Available online: https:\/\/www.cbos.pl\/EN\/publications\/reports.php."},{"key":"ref_43","unstructured":"CBOS (2021, September 13). Attitudes to Vaccination against COVID-19. Available online: https:\/\/www.cbos.pl\/EN\/publications\/reports\/2020\/154_20.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Raciborski, F., Jankowski, M., Gujski, M., Pinkas, J., and Samel-Kowalik, P. (2021). Changes in Attitudes towards the COVID-19 Vaccine and the Willingness to Get Vaccinated among Adults in Poland: Analysis of Serial, Cross-Sectional, Representative Surveys, January-April 2021. Vaccines, 9.","DOI":"10.3390\/vaccines9080832"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1080\/21645515.2018.1496766","article-title":"Mandatory and recommended vaccinations in Poland in the views of parents","volume":"14","author":"Klimaszewska","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/5584_2016_193","article-title":"Influenza Vaccination Coverage Among Polish Patients with Chronic Diseases","volume":"968","author":"Wyszkowska","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Murphy, J., Valli\u00e8res, F., Bentall, R.P., Shevlin, M., McBride, O., Hartman, T.K., McKay, R., Bennett, K., Mason, L., and Gibson-Miller, J. (2021). Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat. Commun., 12.","DOI":"10.1038\/s41467-020-20226-9"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cpr.2009.05.003","article-title":"Brave men and timid women? A review of the gender differences in fear and anxiety","volume":"29","author":"McLean","year":"2009","journal-title":"Clin. Psychol. Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and Gender Differences in the Outcomes of Vaccination over the Life Course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1006845025370","article-title":"Gender Differences in the Perception of Genetic Engineering Applied to Human Reproduction","volume":"46","author":"Napolitano","year":"1999","journal-title":"Soc. Indic. Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0963662509335449","article-title":"Gender differences in knowledge and attitude towards biotechnology","volume":"19","author":"Simon","year":"2009","journal-title":"Public Underst. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"27285","DOI":"10.1073\/pnas.2012520117","article-title":"Gender differences in COVID-19 attitudes and behavior: Panel evidence from eight countries","volume":"117","author":"Galasso","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Racine-Brzostek, S.E., Yee, J.K., Sukhu, A., Qiu, Y., Rand, S., Barone, P.D., Hao, Y., Yang, H.S., Meng, Q.H., and Apple, F.S. (2021). More rapid, robust and sustainable antibody responses to mRNA COVID-19 vaccine in convalescent COVID-19 individuals. JCI Insight, 6.","DOI":"10.1172\/jci.insight.151477"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Trougakos, I.P., Terpos, E., Zirou, C., Sklirou, A.D., Apostolakou, F., Gumeni, S., Charitaki, I., Papanagnou, E.D., Bagratuni, T., and Liacos, C.I. (2021). Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and na\u00efve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Med., 19.","DOI":"10.1186\/s12916-021-02090-6"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","article-title":"Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection","volume":"595","author":"Wang","year":"2021","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Rzymski, P., Perek, B., and Flisiak, R. (2021). Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines, 9.","DOI":"10.3390\/vaccines9060559"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Jemielniak, D., and Krempovych, Y. (2021). # AstraZeneca vaccine disinformation on Twitter. medRxiv.","DOI":"10.1101\/2021.04.08.21255107"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Sadoff, J., Le Gars, M., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., de Groot, A.M., Scheper, G., and Hendriks, J. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting. medRxiv.","DOI":"10.1101\/2021.08.25.21262569"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Eshun-Wilson, I., Mody, A., Tram, K.H., Bradley, C., Sheve, A., Fox, B., Thompson, V., and Geng, E.H. (2021). Preferences for COVID-19 vaccine distribution strategies in the US: A discrete choice survey. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0256394"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1286\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:26:26Z","timestamp":1760167586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/9\/11\/1286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["vaccines9111286"],"URL":"https:\/\/doi.org\/10.3390\/vaccines9111286","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,5]]}}}